Direct Access Growth PHIL recently launched a direct to patient program with Tenpoint for YUVEZZI, delivering affordable, transparent pricing, home delivery, and dedicated support. This demonstrates a proven path to scale patient access programs for specialty therapies. There is a clear opportunity to propose PHIL Direct 2.0 to additional brands seeking patient centric fulfillment and payer optimized price points.

Analytics Advantage PHIL Core provides real time, end to end visibility across script, provider, territory, and payer, offering brands granular insights into access performance. Use cases include optimizing payer mixes, tracking brand performance, and justifying program ROI to stakeholders. Position PHIL as the data driven partner that reduces access bottlenecks and accelerates patient onboarding.

Scale Financing PHIL has secured growth focused financing, signaling readiness to scale programs across more products and geographies. This supports rapid onboarding of new brand partners without disproportionate capital risk. Offer scalable deployment and flexible commercial terms aligned with program milestones.

Trusted Partnerships Existing partnerships with Teva, RedHill Biopharma, and Duchesnay demonstrate credibility and proven value in enabling prescription access for diverse therapies. Leverage these success stories to approach similar sized brands seeking streamlined patient access and payer engagement. Use partner driven opportunities to shorten sales cycles.

Specialty Focus PHIL specializes in specialty lite and branded retail therapies, a segment with complex access requirements and payer constraints. This focus aligns with brands seeking efficiency in patient intake, fulfillment, and adherence support. Propose bundled offerings combining PHIL Direct fulfillment, Core analytics, and payer facing insights to capture larger share of access programs.